5 Key Takeaways
-
1
Patient JT, an 86-year-old man, was diagnosed with age-related macular degeneration (AMD) and nonsubfoveal geographic atrophy (GA).
-
2
His ocular examination revealed bilateral areas of GA with preserved central vision, making him a suitable candidate for complement inhibition treatment.
-
3
The patient opted for FDA-approved complement inhibitor treatment every other month after discussing risks and benefits with his physician.
-
4
Complement inhibition treatment aims to slow the progression of GA, although it does not reverse the condition or prevent its growth.
-
5
Selecting ideal candidates for complement inhibition can optimize treatment outcomes for patients with GA secondary to AMD.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.